This clinical trial is focused on studying a kidney disease called Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN). This condition affects the kidneys and can lead to problems with kidney function. The study is testing a treatment called iptacopan, which is taken as a hard gelatin capsule. The purpose of the study is to see if iptacopan can help reduce the amount of protein in the urine, which is a sign of kidney damage, over a period of six months.

Participants in the study will be randomly assigned to receive either iptacopan or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for up to 12 months, with regular check-ups to monitor the participants’ health and the effects of the treatment.

Throughout the study, participants will have their kidney function and overall health closely monitored. This includes measuring the protein levels in their urine and checking their kidney function through blood tests. The study aims to provide valuable information about the safety and effectiveness of iptacopan in treating IC-MPGN, potentially offering a new treatment option for those affected by this kidney disease.